Status:
RECRUITING
The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborating Sponsors:
Nanjing Legend Biotech Co.
Conditions:
Relapsed/Refractory B-cell Malignancies
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the LVIVO-TaVec100 product in the Treatment of Relapsed/Refractory B-cell Malignancies.
Detailed Description
This is an open-label, dose-escalation/dose extension study to assess the safety, tolerability, and efficacy of LVIVO-TaVec100 product in the patient ≥ 18 years of age with relapsed or refractory B-ce...
Eligibility Criteria
Inclusion
- Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up.
- Aged 18-65 years (inclusive).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- At least one evaluable tumor lesion.
- Relapsed and/or refractory NHL , and relapsed and/or refractory CLL with treatment indications
- Life expectancy≥ 3 months
- Clinical laboratory values meet screening visit criteria
- Adequate organ function;
Exclusion
- Subject eligible for this study must not meet any of the following criteria:
- Prior antitumor therapy with insufficient washout period ;
- Prior treatment with other autologous cells or gene therapies other than targeting CD19 autologous CAR-T;
- Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B virus core antibody (HBcAb), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab).
- Known life-threatening allergic reaction, hypersensitivity reaction, or intolerance to study drug excipients and related excipients, including but not limited to DMSO; or those with a history of severe allergic reactions in the past (such as hypersensitivity reactions, or those with severe immune-related reactions such as the need for glucocorticoids to prevent anaphylaxis as assessed by the investigator).
- Lactating women;
Key Trial Info
Start Date :
May 23 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2029
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07002112
Start Date
May 23 2025
End Date
June 30 2029
Last Update
August 12 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of USTC west district
Hefei, Anhui, China, 230000
2
Beijing Gobroad Boren Hospita
Beijing, Beijing Municipality, China, 102206
3
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050000
4
The First Affiliated Hospital of ZHENGZHOU University
Zhengzhou, Henan, China, 450000